Pharmaceuticals Division – a strong player on the Chinese health care market
The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing, Guangzhou, Chengdu and Jiangsu.
Bayer constructed a pharmaceutical production and packaging facility in Beijing from 1995 to 1997, manufacturing solid and semisolid products. To meet the growing needs of the Chinese market, the company invested significantly in the expansion of the company’s Beijing site. The site increased its production capacity several times following the expansion and was equipped with state-of-the-art technology, including the fastest packaging line in both China and the whole Asia-pacific area. In 2011, the Beijing site received the “Good Manufacturing Practice” certification from the Beijing Drug Administration Bureau. It was the first pharmaceutical enterprise in Beijing to receive this certification.
In anticipation of increasing product demand in China, Bayer is investing EUR 100 million to significantly increase the production capacity of its Beijing plant. The planned capacity expansion is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The expansion will include improved logistics for fully automated material handling, analytical laboratories, and high-speed packaging lines.
The Pharmaceuticals Division’ s Radiology business is a world leader in developing and manufacturing contrast agents used in X-ray, computed tomography (CT) and magnetic resonance imaging (MRI), as well as injection systems for diagnostic and therapeutic medical procedures in CT, MRI and cardiovascular and peripheral vascular diseases.
Consumer Health Division – a leading OTC company in China
Bayer’s Consumer Health Division is a leader in the global consumer health marketplace. It operates in more than 100 countries and maintains several manufacturing and research-and-development (R&D) sites.
The division’s rich history of innovation began in 1899 with the introduction of Bayer’s flagship global consumer brand, Bayer Aspirin™. In 2005, Bayer acquired Roche’s OTC business and in October 2014 Bayer completed the acquisition of Merck’s global Consumer Care business. In November 2014, Bayer acquired 100 percent of the shares of the Chinese Dihon Pharmaceutical Group Co., Ltd.
Besides the over-the-counter (OTC) manufacturing sites in Shanghai, Qidong and Kunming, Bayer announced in January 2016 a milestone opening of its state-of-the-art manufacturing site of traditional Chinese medicine and western medicine in the Majinpu bioengineering and pharmaceutical industrial park in Yunnan. The site is Bayer’s second largest OTC manufacturing facility in Asia Pacific, which will greatly enhance the company’s integral capabilities in providing high-quality self-care solutions to meet the diverse healthcare needs of Chinese consumers.
Today, the Consumer Health divison offers to consumers some of the world’s best-known and most trusted over-the-counter medications and dietary supplements. The portfolio includes strong brands in all the medical categories in which the company competes, including Allergy, Analgesics, Cardiovascular Risk Prevention, Cough & Cold, Dermatology, Gastrointestinals, Dietary Supplements.
Currently, the Consumer Health Division sells various influential brands on the Chinese market, including Talcid®, Elevit®, Kangwang®, Clarityne®, Eloson®, Pikangwang®, White & Black®, Canesten® and others.
Crop Science Division – a committed partner of integrated crop solutions in developing sustainable agriculture in China
The Crop Science Division, a world-leading crop protection solution provider, is committed to contributing to a sustainable development of agriculture by introducing innovation into the market. With a highly efficient and innovative portfolio, complete technical services and strong collaborations with local partners, the Crop Science Division China is aligned with the Chinese government’s efforts to modernize Chinese agriculture and dedicated to help farmers improve plant health, get better yields and gain more benefits.
Bayer has been active for over 60 years in Chinese agriculture, marked with constant efforts to introduce new technologies to Chinese farmers, ranging from Decis, an insecticide in early 1980s, to Luna Sensation launched in 2014, a fungicide for a wide range of vegetables and fruit. In March 2015, Crop Science launched 6 new innovative products in China covering crops of rice, corn, wheat, vegetables and fruits. In a total, over 20 new products are planned to be launched by 2020.
As a global player, Bayer’s production site in Hangzhou is not only supplying products for domestic use, but also manufacturing for farmers in Asia and North and Latin America.
The Crop Science Division has also been carrying out projects in cooperation with authorities like the Ministry of Agriculture, the Chinese Academy of Agricultural Sciences as well as joint efforts with public partners on capacity building in agriculture. To support the latest government efforts in rural development, Bayer started collaboration with CITIC Trust in February 2014 on Innovation & Development of Modern Agricultural Technology on the background of Land Transfer. The collaboration aims to introduce financial services via the CITIC Trust, together with technology and innovation through Crop Science to Chinese agriculture, leveraging the rich experience and expertise of the two parties.
In the field of animal health, it offers a number of products for farm and companion animals. Bayer is one of the leading suppliers of veterinary products in China with its head office and a GMP certified plant in Chengdu, Sichuan province.